FRO Peptides score history
Every recorded change to FRO Peptides’s overall score since October 9, 2026, with the audit note written at the time. Scores follow our published methodology; affiliate status never affects them.
- Score today
- 6.50/10
Score today
- Score changes
- 11
Score changes
- Audit entries
- 12
Audit entries
Score over time
Every entry newest first
- Lowered from6.67to6.50(-0.17)
Lab evidence recomputed under the published rule on 6 November 2026: the SUPPLIER adjustment rose from 0.2 to 0.5 under rule A7 because 20 of its 21 Accumark certificates re-issue analyses first completed for other businesses, which is most of them. Lab evidence 7.3 to 7.0.
- Lowered from6.70to6.67(-0.03)
Pricing re-checked on 6 November 2026 after the market medians were recalculated with GhostLabz and NextSelf Labs added pricing 7.7 to 7.5.
- Raised from6.68to6.70(+0.02)
Pricing re-checked on 5 November 2026 after the market medians were recalculated with Peptyes added pricing 7.6 to 7.7.
- Raised from6.67to6.68(+0.01)
Market medians updated after Pacific Edge Labs was added pricing 7.5 to 7.6.
- Raised from6.61to6.67(+0.06)
Core products recomputed on 29 October 2026 (rule A1b): listings added for newly reviewed vendors made NAD+ a core product in place of CJC-1295, so a missing certificate for each now counts at its new weight: lab 7.2 to 7.3.
- Lowered from6.66to6.61(-0.05)
Market medians updated after S1Research was added pricing 7.8 to 7.5.
- Raised from6.38to6.66(+0.28)
Lab score recalculated on 22 October 2026 under the published core-product rule (A1b): a missing certificate on one of the 15 most widely carried products still counts fully, while on any other product it now counts at half weight, so a broad catalogue is not penalised as much for its breadth. Lab 6.7 to 7.2. Note added 22 October 2026: a score on this entry was corrected from 6.65 to 6.66; it had been rounded down instead of half up.
- Lowered from6.76to6.38(-0.38)
Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 7.5 to 6.0, pricing 7.5 to 7.8, operating history 2.5 to 2.0, transparency 6.5 to 4.5.
- Raised from6.49to6.76(+0.27)
Lab evidence re-checked on 20 October 2026 under our coverage rule, which counts a listed product with no published certificate as zero in the lab average. Certificates cover 21 of the 25 products we list that the vendor offers for sale. Lab 6.2 to 6.7.
- Lowered from6.93to6.49(-0.44)
Lab evidence re-checked on 20 October 2026 under our coverage rule, which counts a listed product with no published certificate as zero in the lab average. Certificates cover 21 of the 25 products we list that the vendor offers for sale. Lab 7.0 to 6.2.
- Raised from6.70to6.93(+0.23)
Vendor named its operating entity (Fro Longevity LLC) and added carrier, transit times and free reshipment of lost or damaged parcels to its policies. Both confirmed on the live site. Lab unchanged.
- First publishedat6.70
lab 7.0 / shipping 6.5 / pricing 7.5 / tenure 2.5 / transparency 6.0. Lab held at 7.0 because five certificates are re-issued copies of analyses first issued to another vendor.
Score changes for every vendor are on the score changes page. FRO Peptides may display its current score with the score badge, which updates automatically and has no effect on the score.